TL;DR
The FDA approved Zydus Pharmaceuticals’ generic version of Climara Pro, a hormone therapy patch applied once a week. It is indicated for moderate to severe menopause-related hot flashes and prevention of postmenopausal osteoporosis in women with an intact uterus. The FDA has not provided availability or pricing details.
The U.S. Food and Drug Administration approved Zydus Pharmaceuticals’ generic version of Climara Pro, a combination estradiol and levonorgestrel patch applied once a week. The treatment is approved for women with an intact uterus to address moderate to severe menopause-related vasomotor symptoms and to help prevent postmenopausal osteoporosis; when it will be available and at what price remains unknown.
The FDA said the generic contains estradiol and levonorgestrel in a transdermal system delivering 0.045 milligrams of estradiol per day and 0.015 milligrams of levonorgestrel. The agency described it as therapeutically equivalent to Climara Pro, which is made by Bayer. A generic approval does not by itself establish when the product will reach pharmacies or what patients will pay.
Unlike estrogen-only patches, the approved product combines estrogen and progestogen in one patch. The FDA says the product is specifically approved for women with an intact uterus; its progestogen component is included to reduce the risk of endometrial hyperplasia that can occur with estrogen use alone. Patients should consult a qualified health professional about whether this therapy is appropriate for them.
The agency listed contraindications that include undiagnosed abnormal genital bleeding, breast cancer or a history of breast cancer, estrogen-dependent neoplasia, and certain clotting conditions. It also listed active or previous deep vein thrombosis or pulmonary embolism, active or previous arterial thromboembolic disease, liver disease, and certain inherited or other thrombophilic disorders. Listed common adverse reactions, occurring in at least 5% of patients, include application-site reactions, vaginal bleeding, breast pain, headache, back pain, depression, pain, upper respiratory infection and flu syndrome.
A Weekly Combination Patch Gets a Generic
The approval adds a generic option for a once-weekly combination therapy used for specified menopause-related symptoms and osteoporosis prevention. The FDA says generic competition can support affordability and access, but its announcement does not give a price, estimate savings, or say how much competition this particular product will face.
For patients and clinicians, the product’s combination formulation and once-weekly schedule are relevant features, but they do not make it suitable for everyone. The agency’s list of contraindications underscores that treatment choice depends on a patient’s health history and clinical circumstances. The FDA’s approval establishes the generic’s therapeutic equivalence to the brand product; it does not amount to individualized medical advice.
Acting FDA Commissioner Kyle Diamantas said the approval is intended to expand access to treatment. FDA Center for Drug Evaluation and Research Director Michael Davis pointed to weekly dosing as a possible practical advantage over daily oral medication. Those are agency statements about the approval’s potential value, not findings in the release that quantify improved adherence or patient outcomes.
As an affiliate, we earn on qualifying purchases.
How the Generic Compares With Climara Pro
Climara Pro is a registered trademark of Bayer. The FDA identifies the newly approved generic as estradiol and levonorgestrel transdermal system and names Zydus Pharmaceuticals (USA) Inc. as its manufacturer. The approval is for the same two active ingredients and strengths described in the FDA release, with the same listed indications and once-weekly application.
The FDA says nine out of 10 prescriptions filled in the United States are for generic drugs, a broad national figure it uses to explain the role of generics. That statistic is not a projection of use for this patch. The agency directed readers to its Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, for information about approved products and therapeutic-equivalence evaluations.
“Menopause is a universal experience for women, and it can greatly affect a person’s quality of life. This approval makes effective treatment more accessible.”
— Kyle Diamantas, acting FDA commissioner
As an affiliate, we earn on qualifying purchases.
Availability, Price and Patient Suitability
The FDA release does not say when Zydus will begin distributing the patch, which pharmacies may stock it, or how its price will compare with Climara Pro. The agency advises consumers to contact the manufacturer for availability information. Approval alone does not confirm immediate market supply or a specific reduction in out-of-pocket costs.
The announcement also does not provide a new clinical trial analysis, patient-specific guidance, or details on how prescribers should choose among hormone therapy options. The FDA lists conditions that rule out use and adverse reactions, but patients should discuss the product’s risks and benefits with a qualified health professional. The release does not describe an individual patient’s likely response.
As an affiliate, we earn on qualifying purchases.
Manufacturer Supply and Pharmacy Access
The next practical development is Zydus Pharmaceuticals’ distribution and availability information. The FDA said people seeking details about when the generic can be obtained should contact the manufacturer. Pharmacy listings and pricing will clarify whether the approval translates into a readily accessible alternative.
The FDA’s Orange Book provides a public reference for approved drug products and therapeutic-equivalence evaluations. Until further manufacturer or pharmacy information is available, the confirmed development is the agency’s approval—not a launch date, a guaranteed supply, or a particular price.
transdermal hormone replacement therapy
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the FDA approve?
The FDA approved Zydus Pharmaceuticals’ generic estradiol and levonorgestrel transdermal system, a once-weekly patch that the agency says is therapeutically equivalent to Climara Pro.
Who is the patch approved for?
It is approved for women with an intact uterus for moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis. A qualified health professional can advise on individual suitability.
Why does the patch contain both hormones?
The patch combines estrogen and progestogen. The FDA says the progestogen component is included to reduce the risk of endometrial hyperplasia that can occur with estrogen use alone.
When will the generic be available, and how much will it cost?
The FDA announcement does not state a launch date or price. It advises consumers to contact Zydus Pharmaceuticals for availability information.
What safety information did the FDA list?
The FDA listed contraindications including certain cancers, unexplained genital bleeding, blood clots or clotting disorders, and liver disease. Common adverse reactions include application-site reactions, vaginal bleeding, breast pain and headache. Patients should review the product’s risks with a qualified health professional.
Source: primary
